Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/10/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Peter R. Mueller

Wrong Dr. Peter R. Mueller?

President of Research and Develop...

Pronutria Biosciences
Phone: (617) ***-****  HQ Phone
Email: p***@***.com
Pronutria Inc
840 Memorial Drive Third Floor
Cambridge , Massachusetts 02139
United States

Company Description: Pronutria created a revolutionary platform for identifying protein nutrients from within the human diet that have potent pharmacological effects, opening a vast...   more

Employment History

Board Memberships and Affiliations


  • PhD , Chemistry
    Albert Einstein University of Ulm , Germany
  • undergraduate degree
    Albert Einstein University of Ulm , Germany
  • Ph.D. , Chemistry
    Albert Einstein University of Ulm , Germany
146 Total References
Web References
Peter Mueller, PhD President ..., 10 Nov 2015 [cached]
Peter Mueller, PhD President of R&D and Chief Scientific Officer
"With a proprietary platform of over ..., 20 Oct 2015 [cached]
"With a proprietary platform of over 1 billion protein and fragment sequences to identify disease specific product candidates, we are unlocking the regenerative potential of homeostatic amino acid biology to transform the lives of patients and their families," said Dr. Peter Mueller, President of R&D and Chief Scientific Officer at Pronutria Biosciences.
Peter Mueller, ..., 10 Nov 2015 [cached]
Peter Mueller, PhD
President of R&D and Chief Scientific Officer
Prior to his time at Pronutria Biosciences, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible for build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain as well as Clinical and Non-Clinical Development, Regulatory and Medical Affairs and Patient Safety. Key areas of Vertex' R&D have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submissions for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) and its European counterpart the Galenus Preis (Kalydeco). The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration. In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD,Cancer, TB). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a PhD in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. Special Fields of studies are Synthetic Organic Chemistry, Computational Chemistry (Cheminformatics and Bioinformatics), RNA-Biophysics, Atherosclerosis Research, IMID (Immune Mediated Inflammatory Diseases), Neurodegenerative Diseases, Infection, Oncology, Gene/ Epigenetic Technology and Management Strategies. He is a (Board) member of various scientific and political societies, such as the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (UK); US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, IRI, RNA-Society, ASAP, AAAS (USA), Harvard Accelerator Fund, and SAB for Keystone Conferences and serves also on the Board of Inhibikase. Before he left Connecticut to join Vertex, Dr. Mueller was a member of Governor Roland's Council on Economic Competitiveness and Technology for the State of Connecticut (USA).
Vertex Announces Retirement of Peter Mueller, Ph.D. (NASDAQ:VRTX), 31 Oct 2014 [cached]
Vertex Announces Retirement of Peter Mueller, Ph.D. | Read more | « Previous Release Vertex Announces Retirement of Peter Mueller, Ph.D. (NASDAQ:VRTX)
Vertex Announces Retirement of Peter Mueller, Ph.D.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller
Dr. Mueller's retirement will be effective October 31, 2014 , following a planned transition period. Dr. Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation.
"Peter is a visionary who embodied Vertex's fearless pursuit of transformational medicines," said Jeffrey Leiden , M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "I thank Peter for his leadership, innovation and dedication to Vertex over the past decade."
to oversee the company's drug discovery efforts following Dr. Mueller's retirement.
In 2014, Peter Mueller left ..., 29 Sept 2015 [cached]
In 2014, Peter Mueller left his position as chief science officer at Vertex Pharmaceuticals (VRTX) to take on the position of president of research and development and chief science officer at Pronutria. When Mueller joined Pronutria he said he was excited about “restoring amino acid imbalance� as a means of developing therapeutics for debilitating diseases.
Other People with the name "Mueller":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.